Pre-operative tranexemic acid versus eethamsylate in reducing blood loss during cesarean sectio
Not Applicable
Completed
- Conditions
- Pregnancy and ChildbirthDecreasing blood loss
- Registration Number
- PACTR201802002761404
- Lead Sponsor
- Airforce specialized Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Female
- Target Recruitment
- 120
Inclusion Criteria
All women undergoing elective cesarean section except those with placenta Previa
Exclusion Criteria
Emergency cesarean section
Placenta previa
Any contraindications or hypersensitivity to any of the treatments
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie tranexamic acid's antifibrinolytic effects in cesarean section blood loss reduction?
How does pre-operative tranexamic acid compare to ethamsylate in managing postpartum hemorrhage in cesarean deliveries?
Are there specific biomarkers that predict response to antifibrinolytic agents like tranexamic acid in obstetric hemorrhage management?
What are the potential adverse events associated with tranexamic acid use in pregnant patients and how are they managed?
What combination therapies or alternative antifibrinolytic agents are being explored for reducing blood loss during cesarean sections?